BBIO Earnings & Financial Statements
BridgeBio Pharma, Inc.
$67.15
+$2.20(+3.40%)
36
Overall
40
Value
18
Tech
52
Quality
Market Cap
$12.69B
Volume
1.06M
52W Range
$52.75 - $93.42
Target Price
$108.35
BBIO earnings and financial statements: BridgeBio Pharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BBIO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $502.08M | $221.90M | $9.30M | $77.65M | $69.72M |
| Cost of revenue | $20.96M | $3.88M | $2.45M | $3.43M | $3.11M |
| Operating income | -$523.41M | -$592.97M | -$607.37M | -$512.20M | -$576.63M |
| EBITDA | -$663.10M | -$433.55M | -$565.47M | -$397.44M | -$533.83M |
| Net income | -$724.93M | -$535.76M | -$643.20M | -$481.18M | -$562.54M |
| EPS (diluted) | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $936.02M | $919.34M | $546.38M | $623.04M | $1.01B |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B |
| Shareholders’ equity | -$2.09B | -$1.47B | -$1.35B | -$1.25B | -$870.41M |
| Cash and equivalents | $570.12M | $681.10M | $375.94M | $376.69M | $393.77M |
| Long-term debt | $3.81M | $4.70M | $455.43M | $443.27M | $448.18M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$445.91M | -$520.73M | -$527.72M | -$419.49M | -$497.93M |
| Capital expenditure | -$9.59M | -$8.91M | -$1.31M | -$6.32M | -$48.25M |
| Free cash flow | -$455.50M | -$529.63M | -$529.03M | -$425.81M | -$546.18M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BBIO | $67.15 | +3.4% | 1.06M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |